minocycline and Low-Back-Pain

minocycline has been researched along with Low-Back-Pain* in 3 studies

Trials

1 trial(s) available for minocycline and Low-Back-Pain

ArticleYear
Assessing the potential anti-neuroinflammatory effect of minocycline in chronic low back pain: Protocol for a randomized, double-blind, placebo-controlled trial.
    Contemporary clinical trials, 2023, Volume: 126

    Both preclinical studies, and more recent clinical imaging studies, suggest that glia-mediated neuroinflammation may be implicated in chronic pain, and therefore might be a potential treatment target. However, it is currently unknown whether modulating neuroinflammation effectively alleviates pain in humans. This trial tests the hypothesis that minocycline, an FDA-approved tetracycline antibiotic and effective glial cell inhibitor in animals, reduces neuroinflammation and may reduce pain symptoms in humans with chronic low back pain.. This study is a randomized, double-blind, placebo-controlled clinical trial. Subjects, aged 18-75, with a confirmed diagnosis of chronic (≥ six months) low back pain (cLBP) and a self-reported pain rating of at least four out of ten (for at least half of the days during an average week) are enrolled via written, informed consent. Eligible subjects are randomized to receive a 14-day course of either active drug (minocycline) or placebo. Before and after treatment, subjects are scanned with integrated Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) using [. ClinicalTrials.gov (NCT03106740).

    Topics: Chronic Pain; Double-Blind Method; Humans; Low Back Pain; Minocycline; Neuroinflammatory Diseases; Randomized Controlled Trials as Topic; Receptors, GABA; Treatment Outcome

2023

Other Studies

2 other study(ies) available for minocycline and Low-Back-Pain

ArticleYear
Prevention and reversal of latent sensitization of dorsal horn neurons by glial blockers in a model of low back pain in male rats.
    Journal of neurophysiology, 2017, 10-01, Volume: 118, Issue:4

    In an animal model of nonspecific low back pain, recordings from dorsal horn neurons were made to investigate the influence of glial cells in the central sensitization process. To induce a latent sensitization of the neurons, nerve growth factor (NGF) was injected into the multifidus muscle; the manifest sensitization to a second NGF injection 5 days later was used as a read-out. The sensitization manifested in increased resting activity and in an increased proportion of neurons responding to stimulation of deep somatic tissues. To block microglial activation, minocycline was continuously administered intrathecally starting 1 day before or 2 days after the first NGF injection. The glia inhibitor fluorocitrate that also blocks astrocyte activation was administrated 2 days after the first injection. Minocycline applied before the first NGF injection reduced the manifest sensitization after the second NGF injection to control values. The proportion of neurons responsive to stimulation of deep tissues was reduced from 50% to 17.7% (

    Topics: Animals; Astrocytes; Central Nervous System Sensitization; Citrates; Low Back Pain; Male; Microglia; Minocycline; Nerve Growth Factor; Posterior Horn Cells; Rats; Rats, Sprague-Dawley

2017
Changes in white blood cell counts in men undergoing thrice-weekly prostatic massage, microbial diagnosis and antimicrobial therapy for genitourinary complaints.
    British journal of urology, 1998, Volume: 81, Issue:3

    To report changes in the white blood cell (WBC) counts in expressed prostatic secretions (EPS) in men with pelvic symptoms undergoing thrice-weekly prostatic massage combined with antimicrobial therapy.. The study comprised a retrospective analysis of the records of 35 patients (mean age 45.3 years, range 28-70, SD, 12.03) with pelvic pain, pain in the lower back, obstructive urinary symptoms, irritative urinary symptoms, or sexual dysfunction, who had undergone the same diagnosis and treatment protocol in a genitourinary clinic in Manila, Philippines, from September 1992 to September 1995.. EPS were obtained 347 times in 35 patients (median 9 times per patient, range 6-16). In 26 of the 35 (74%) patients the WBC count in the EPS was < 10 per oil-immersion field (OIF, x1000) at the first prostatic massage. In 34 of 35 (97%) patients the WBC count rose to > or = 10 as prostatic massage continued on a thrice-weekly schedule. The mean (range, SD) initial WBC count in the EPS was 8.4 (1-48, 8.43) and the maximum was 40.9 (6-60, 19.05); the difference between these values was 32.5 (3-57, 18.78; 95% confidence interval 26.1-40.1) and the difference was statistically significant (paired t-test, P < 0.001).. The classification of patients into those with prostatodynia or prostatitis based on one EPS examination is misleading and thrice-weekly massage of the prostate is better than a single collection of EPS to obtain the most purulent sample for Gram staining and culture.

    Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antibiotics, Antineoplastic; Bacterial Infections; Drug Therapy, Combination; Humans; Leukocyte Count; Low Back Pain; Male; Massage; Middle Aged; Minocycline; Ofloxacin; Pain; Pelvic Pain; Prostatitis; Retrospective Studies; Sexual Dysfunction, Physiological; Urinary Retention

1998